1. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy

   • A. Küpfer
   • C. Aeschlimann
   • T. Cerny

   MINI REVIEW Pages: 249 - 252

2. What happens to long-term medication when general practice patients are referred to hospital?

   • W. Himmel
   • M. Tabache
   • M. M. Kochen

   PHARMACODEPIDEMIOLOGY AND PRESCRIPTION Pages: 253 - 257

3. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients

   • B. Persson
   • M. Stimpel

   PHARMACODYNAMICS Pages: 259 - 264

4. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure

   • Y. M. Pinto
   • D. J. van Veldhuisen
   • K. I. Lie

   PHARMACODYNAMICS Pages: 265 - 268

5. Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antagonist FK-24 in asthmatic subjects

   • D. Schmidt
   • R. A. Jörres
   • H. Magnussen

   PHARMACODYNAMICS Pages: 269 - 273

6. Effects of short-term exposure to high-dose inhaled corticosteroids on novel markers of bone metabolism

   • A. Grove
   • L. C. McFarlane
   • B. J. Lipworth

   PHARMACODYNAMICS Pages: 275 - 277

7. Digital pulse plethysmography as a non-invasive method for predicting drug-induced changes in left ventricular preload

   • E. Stengele
   • F. Winkler
   • H. Roskamm

   PHARMACODYNAMICS Pages: 279 - 282

8. Stereoselective distribution of tiaprofenic acid in synovium and cartilage in osteoarthritic patients

   • F. Lapicque
   • D. Mainard
   • P. Netter

   PHARMACOKINETICS AND DISPOSITION Pages: 283 - 287

9. Pharmacokinetics of flosequinan in patients with heart failure

   • D. P. Nicholls
   • A. Droogan
   • I. D. Hind

   PHARMACOKINETICS AND DISPOSITION Pages: 289 - 291

10. Pharmacokinetics and absolute bioavailability of lansoprazole

    • J. Gerloff
    • A. Mignot
    • K. Heintze

    PHARMACOKINETICS AND DISPOSITION Pages: 293 - 297

11. Comparison of the pharmacokinetics of tirilazad mesylate in healthy volunteers and stable subjects with mild liver cirrhosis

    • L. K. Pearson
    • J. C. Fleishaker
    • G. R. Peters

    PHARMACOKINETICS AND DISPOSITION Pages: 299 - 304

12. Effect of moderate or severe liver dysfunction on the pharmacokinetics of γ-hydroxybutyric acid

    • S. D. Ferrara
    • L. Tedeschi
    • P. Palatini

    PHARMACOKINETICS AND DISPOSITION Pages: 305 - 310

13. Effect of food intake on pharmacokinetics and effects of a new thromboxane A2 receptor antagonist, S-1452

    • A. Fujimura
    • T. Shiga
    • T. Kotegawa

    PHARMACOKINETICS AND DISPOSITION Pages: 311 - 314

14. Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone – a novel antiarrhythmic agent

    • R. Koytchev
    • R.-G. Alken
    • M. Greenwood

    PHARMACOKINETICS AND DISPOSITION Pages: 315 - 319

15. Absolute bioavailability of fluoride from disodium monofluorophosphate and enteric-coated sodium fluoride tablets

    • P. van Asten
    • S. A. Duursma
    • A. van Dijk

    PHARMACOKINETICS AND DISPOSITION Pages: 321 - 326

16. Plasma and skin suction-blister-fluid pharmacokinetics and time course of the effects of oral mizolastine

    • O. Chosidow
    • C. Dubruc
    • J. Revuz

    PHARMACOKINETICS AND DISPOSITION Pages: 327 - 333

17. A single dose of ursodiol does not affect cyclosporine absorption in liver transplant patients

    • C. W. Maboundou
    • G. Paintaud
    • P. R. Bechtel

    PHARMACOKINETICS AND DISPOSITION Pages: 335 - 337

18. Exercise increases plasma concentrations of (R)- and (S)-propranolol

    • K. Stoschitzky
    • M. Schumacher
    • W. Lindner

    PHARMACOKINETICS AND DISPOSITION Pages: 339 - 342